P. Prasit

发表

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

M. Percival, D. Riendeau, B. Kennedy, 1999, Bioorganic & medicinal chemistry letters.

Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity.

N. Cosford, P. Prasit, B. Muñoz, 2004, Journal of medicinal chemistry.

NEW CLASS OF POTENT LIGANDS FOR THE HUMAN PERIPHERAL CANNABINOID RECEPTOR

P. Prasit, Y. Leblanc, D. Guay, 1996 .

Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5‐Lipoxygenase‐Activating Protein (FLAP)

D. Lorrain, P. Prasit, J. Evans, 2010, Clinical pharmacology and therapeutics.

A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.

P. Prasit, C. Brideau, C. Chan, 1993, Journal of lipid mediators.

5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.

P. Prasit, J. Evans, J. Gauthier, 1991, Molecular pharmacology.

The discovery of a new structural class of potent orally active leukotriene D4 antagonists

R. Young, P. Prasit, A. Ford-hutchinson, 1992 .

Development of MK 0591: An Orally Active Leukotriene Biosynthesis Inhibitor with a Novel Mechanism of Action

P. Prasit, P. Vickers, 1995 .

Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein.

P. Prasit, Z. Wang, S. Charleson, 1994, European journal of pharmacology.

Development of L-689,065 - the prototype of a new class of potent 5-lipoxygenase inhibitors

D. Riendeau, P. Prasit, S. Charleson, 1992 .

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

Jilly F. Evans, D. Lorrain, P. Prasit, 2011, Journal of Pharmacology and Experimental Therapeutics.

Synthesis and biological evaluation of 5,6-diarylimidazo[2.1-b]thiazole as selective COX-2 inhibitors

D. Riendeau, P. Prasit, C. Brideau, 1997 .

One pot biaryl synthesis via in situ boronate formation

Yongxin Han, P. Prasit, A. Giroux, 1997 .

A new class of leukotriene biosynthesis inhibitors: The discovery of MK0591

D. Riendeau, R. Young, P. Prasit, 1992 .

A new class of leukotriene biosynthesis inhibitors: The development of ((4-(4-chlorophenyl)-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid, L-674,636

R. Young, P. Prasit, J. Evans, 1991 .

5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.

P. Prasit, J. Evans, S. Léger, 1992, Molecular pharmacology.

A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair.

P. Prasit, J. Gauthier, R. Zamboni, 1998, Bioorganic & medicinal chemistry letters.

From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors.

P. Prasit, C. Chan, S. Charleson, 1997, Advances in experimental medicine and biology.

From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors

C. Bayly, D. Denis, P. Prasit, 1996 .

Pyridazinones as selective cyclooxygenase-2 inhibitors.

D. Riendeau, P. Prasit, C. Brideau, 2003, Bioorganic & medicinal chemistry letters.

A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.

D. Riendeau, P. Prasit, C. Brideau, 1999, Bioorganic & medicinal chemistry letters.

SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.

D. Riendeau, S. Boyce, P. Prasit, 1999, Bioorganic & medicinal chemistry letters.

Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).

D. Riendeau, R. Young, P. Prasit, 2000, Bioorganic & medicinal chemistry letters.

The methoxymercuration of a 6-deoxyhex-5-enopyranoside derivative and reactions of the products

P. Prasit, R. Ferrier, 1980 .

2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.

R Gordon, D. Riendeau, P. Prasit, 1999, Journal of medicinal chemistry.

Synthesis and biological evaluation of 2,3-diarylthiophenes as selective cox-2 inhibitors. part II: Replacing the heterocycle

D. Riendeau, P. Prasit, W. Cromlish, 1996 .

A new series of selective COX-2 inhibitors : 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles

P. Prasit, C. Brideau, C. Chan, 1997 .

Unsaturated carbohydrates. Part 25. Abbreviated synthesis of the insect pheromone (+)-exo-brevicomin from a nona-3,8-dienulose derivative

P. Prasit, R. Ferrier, 1983 .

Functionalised carbocycles from carbohydrates. Part 2. The synthesis of 3-oxa-2-azabicyclo[3.3.0]octanes. X-Ray crystal structure of (1R,5S)-6-exo,7-endo,8-exo-triacetoxy-N-methyl-4-endo-phenylthio-3-oxa-2-azabicyclo[3.3.0]octane

R. Furneaux, P. Tyler, P. Prasit, 1983 .

A general route to optically pure prostaglandins from a D-glucose derivative

P. Prasit, R. Ferrier, 1982 .

Carbocycles from carbohydrates: A simple route to an enantiomerically pure prostaglandin intermediate

P. Prasit, P. Bélanger, 1988 .

SYNTHESIS AND BIOLOGICAL EVALUATION OF BOTH ENANTIOMERS OF L-761,000 AS INHIBITORS OF CYCLOOXYGENASE 1 AND 2

Yves Leblanc, Daniel Guay, Petpiboon Prasit, 1996 .

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor

J. Falgueyret, M. Percival, D. Riendeau, 1997, British journal of pharmacology.

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

R Gordon, J. Falgueyret, M. Percival, 2001, The Journal of pharmacology and experimental therapeutics.

Inversion of configurations of contiguous carbinol centres: application to the synthesis of both enantiomers of natural products from the same enantiomerically pure starting material

G. Robertson, P. Prasit, J. Rokach, 1990 .

Routes to prostaglandins from sugars

P. Prasit, R. Ferrier, 1983 .

Functionalised carbocycles from carbohydrates. Part 3. The synthesis of the epoxy lactone prostaglandin intermediate via an isoxazolidine derivative. X-Ray crystal structure of (1R,5R)-6-exo,7-endo-dibenzoyloxy-8-exo-iodo-3-oxo-2-oxabicyclo[3.3.0]octane

P. Prasit, G. Gainsford, R. Ferrier, 1983 .

FUNCTIONALIZED CARBOCYCLES FROM CARBOHYDRATES. PART 3. THE SYNTHESIS OF THE EPOXY LACTONE PROSTAGLANDIN INTERMEDIATE VIA AN ISOXAZOLIDINE DERIVATIVE. X-RAY CRYSTAL STRUCTURE OF (1R,5R)-6-EXO,7-ENDO-BIS(BENZOYLOXY)-8-EXO-IODO-3-OXO-2-O

P. Prasit, G. Gainsford, R. Ferrier, 1983 .

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

H Perrier, R Gordon, M. Percival, 1999, The Journal of pharmacology and experimental therapeutics.

An Efficient Synthesis of LTD4 Antagonist L-699,392.

P. Prasit, Y. Leblanc, R. Zamboni, 1993 .

Synthesis of Rofecoxib, (MK 0966, Vioxx® 4-(4′-Methylsulfonylphenyl)-3-Phenyl-2(5H)-Furanone), a Selective and Orally Active Inhibitor of Cyclooxygenase-2

P. Prasit, J. Gauthier, Y. Leblanc, 2001 .

Substituted heterocyclic analogs as selective COX-2 inhibitors in the flosulide class.

D. Riendeau, P. Prasit, C. Chan, 1999, Bioorganic & medicinal chemistry letters.

ChemInform Abstract: Synthesis of Rofecoxib, (MK 0966, Vioxx® 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)-furanone), a Selective and Orally Active Inhibitor of Cyclooxygenase-2.

P. Prasit, J. Gauthier, Y. Leblanc, 2002 .

A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

D. Lorrain, P. Prasit, T. J. Seiders, 2010, British journal of pharmacology.

A role for oleoylethanolamide in chronic lymphocytic leukemia

M. Eiden, P. Prasit, Y. Shi, 2014, Leukemia.

Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.

D. Riendeau, P. Prasit, C. Brideau, 2002, Bioorganic & medicinal chemistry letters.

Chapter 21. Selective Cyclooxygenase-2 Inhibitors

D. Riendeau, P. Prasit, 1997 .

3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.

D. Riendeau, P. Prasit, C. Brideau, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and Biological Evaluation of 2,3-Diarylthiophenes as Selective COX-2 Inhibitors. Part 2. Replacing the Heterocycle

D. Riendeau, P. Prasit, W. Cromlish, 1996 .

Translocation of HL-60 cell 5-lipoxygenase. Inhibition of A23187- or N-formyl-methionyl-leucyl-phenylalanine-induced translocation by indole and quinoline leukotriene synthesis inhibitors.

P. Prasit, J. Evans, S. Kargman, 1991, The Journal of biological chemistry.

A New Series of Selective COX-2 Inhibitors: 5,6-Diarylthiazolo(3,2-b)( 1,2,4)triazoles.

P. Prasit, C. Brideau, C. Chan, 1997 .

Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.

P. Prasit, S. Charleson, J. Evans, 1992, Molecular pharmacology.

Synthesis of a radioactive photoaffinity arachidonic acid analog

P. Prasit, H. Perrier, Zhaoyin Wang, 1994 .

Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors.

D. Riendeau, P. Prasit, C. Brideau, 1999, Bioorganic & medicinal chemistry letters.

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.

D. Riendeau, D. Denis, P. Prasit, 1992, Canadian journal of physiology and pharmacology.

New Class of Potent Ligands for the Human Peripheral Cannabinoid Receptor.

P. Prasit, Y. Leblanc, D. Guay, 1997 .